No Data
No Data
gtja: Bullish on innovative drugs policy, expected to continue to advance. Chinese patent medicine centralized procurement may face accelerated expansion.
With the support of the entire chain, innovative drugs have seen a series of bullish policies introduced in various regions, and favorable policies are expected to continue to advance in the future; centralized procurement of chinese patent medicine may accelerate its expansion.
Trending Industry Today: WUXI APPTEC Leads Losses In Biotechnology Stocks
Stocks anomaly | Akeso (09926) surged over 3% with the recent approval of the first non-tumor product. A new round of stock placement has been completed.
Akeso (09926) rose more than 3%, as of the deadline for submission, rose by 2.95%, at 66.4 Hong Kong dollars, with a turnover of 0.199 billion Hong Kong dollars.
CICC: Maintains a 'outperform' rating on Akeso (09926) with the target price raised to HK$90.
Akeso's new drug Yixining (Inoliximab, PCSK9) has applied for marketing approval and has been approved by the China National Medical Products Administration.
Hong Kong stocks moving abnormally | Akeso (09926) surged over 3% in the morning, proposing to issue approximately 4.99% discounted for a total of 31.7 million shares for the research and development of biopharmaceutical products.
Akeso (09926) rose more than 3% in the morning, as of the deadline, up 2.71% to HK$66.25, with a turnover of HK$1.069 billion.
Morgan Stanley Acting as Placing Agents for Akeso
No Data
No Data
MayFlower : It was predictable..
Midnite52 : yep